This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Tuesday's Winners & Losers: MoneyGram International

Citigroup (C), ravaged by its exposure to subprime mortgages, wrote down a pretax sum of $18.1 billion and took a fourth-quarter loss of $9.83 billion, or $1.99 a share. That reverses last year's profit of $5.13 billion, or $1.03 a share, and it compares with Wall Street targets for a loss of $1.03 a share, per Thomson Financial. Revenue plummeted 69.7% to $7.22 billion, also thanks to the massive subprime writedowns.

Citi shares were recently sliding $2.26, or 7.8%, to $26.80, in sharp retreat from the upward float they had enjoyed over the past week.

On the uptick, Arena Therapeutics (ARNA) picked up $1.14, or 15%, to $8.55, after an upgrade from Bank of America analyst William Ho. He raised his rating on the stock to buy from neutral, predicting that a data safety monitoring committee reviewing echocardiograms won't find a link between Arena's obesity drug Lorcaserin and heart valve damage.

Elsewhere, Lifecore Biomedical (LCBM) said Tuesday that it will be acquired by Warburg Pincus for $17 a share in cash, a 30% premium over the average price of the shares for the last 30 days, valuing the company at about $239 million. The company expects the transaction will close before the end of the first quarter. Shares climbed $3.89, or 30.3%, to $16.73.

Back in earnings, Boston bank State Street (STT) said fourth-quarter income sank 27.8% year over year to $223 million, 57 cents a share. As previously disclosed, that's primarily because the Boston bank set aside 71 cents a share for covering potential legal costs related to losses from its mortgage-backed investments. Even excluding that one-off expense, however, the bank still came in 7 cents shy of the $1.35 per-share analyst consensus. Shares surrendered 6.1% to $79.70 in recent trading.

Shares of Minneapolis-based money-transfer and payment-processing servicer MoneyGram International (MGI) were cut in half, down 50.7% at $6. The company announced late Monday that, from Sept. 30 to Nov. 30, its investment portfolio lost an unrealized $571 million, bringing total losses to $860 million. MoneyGram is negotiating with Thomas H. Lee Partners for a cash injection of about $800 million. Under the proposed deal, Thomas H. Lee Partners would control between 60% and 65% of MoneyGram.

Also losing ground was Memsic (MEMS), shares of which ceded 19.4% to $6.78. The Andover, Mass., provider of semiconductor and systems solutions exercised its overallotment option to buy 823,000 shares of its stock at $10 a share, the price at the company's IPO, less underwriting discounts and commissions.

This article was written by a staff member of TheStreet.com.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs